Company: PGEN
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001356090-25-000019
Chunk: 17

Company: PRECIGEN, INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
Lease liabilities(95)40 Net cash used in operating activities(16,325)(14,090)

The accompanying notes are an integral part of these condensed consolidated financial statements.

9

Precigen, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 Three Months Ended  March 31,(Amounts in thousands)20252024Cash flows from investing activitiesPurchases of investments$(10,408)$(17,190)Sales and maturities of investments4,573 45,583 Purchases of property, plant and equipment(622)(4,351)Proceeds from sale of assets— 3 Net cash provided by (used in) investing activities(6,457)24,045 Cash flows from financing activitiesPayment of issuance cost related to 2024 public offering of shares(355)— Payments to taxing authorities in connection with shares directly withheld from employees(474)— Proceeds from stock option exercises150 — Net cash used in financing activities(679)— Effect of exchange rate changes on cash, cash equivalents, and restricted cash2 (60)Net increase (decrease) in cash, cash equivalents, and restricted cash(23,459)9,895 Cash, cash equivalents, and restricted cashBeginning of period29,517 7,848 End of period$6,058 $17,743 Supplemental disclosure of cash flow informationCash paid during the period for interest$— $3 Significant noncash activitiesPurchases of property and equipment included in accounts payable and other accrued liabilities$866 $2,109 Issuance costs included in accounts payable and other accrued liabilities$537 $— 

The accompanying notes are an integral part of these condensed consolidated financial statements.

10

Precigen, Inc. and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

(Amounts in thousands, except share and per share data)

1. Organization

Precigen, Inc. ("Precigen"), a Virginia corporation, is a dedicated discovery and clinical-stage biopharmaceutical company advancing the next generation of gene and cell therapies with the overall goal of improving outcomes for patients with significant unmet medical needs.  Precigen is leveraging its proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Precigen’s